Answers are grounded in this paper and cite their sources.
Phase 2 study evaluates combination therapy in metastatic NSCLC, suggesting improved antitumor response implications.
Acasunlimab (DuoBody®-PD-L1x4-1BB) is a bispecific antibody immunotherapy designed to reinvigorate antitumor activity via conditional 4-1BB activation dependent on co-PD-L1 binding. Acasunlimab was evaluated in a Ph2 study (NCT05117242) in checkpoint inhibitor (CPI)- and chemotherapy (chemo)-treated PD-L1+ metastatic NSCLC as monotherapy (Arm A: 100 mg Q3W x2 cycles then 500 mg Q6W) or in combination (combo) with pembrolizumab (pembro) to maximize PD-1 blockade (Arm B: 100 mg + pembro 200 mg Q3W; Arm C: 100 mg + pembro 400 mg Q6W).
No takes yet. Share an insight, caveat, or question.
Besse et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: